Acro Biomedical Co., Ltd. (ACBM)
OTCMKTS · Delayed Price · Currency is USD
0.0260
0.00 (0.00%)
At close: Jun 16, 2026
Acro Biomedical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0 | 0 | 0 | 0 | 0.01 | 0.1 |
Cash & Short-Term Investments | 0 | 0 | 0 | 0 | 0.01 | 0.1 |
Cash Growth | 13930.77% | 760.92% | 26.60% | -93.58% | -93.86% | 425.56% |
Receivables | - | - | - | - | 0.64 | 0.6 |
Inventory | - | - | - | - | 0.01 | 0.01 |
Prepaid Expenses | - | 0.01 | - | 0 | 0 | 0 |
Other Current Assets | - | - | 0 | - | - | - |
Total Current Assets | 0 | 0.01 | 0.01 | 0 | 0.66 | 0.71 |
Property, Plant & Equipment | - | - | 0.03 | 0.05 | 0.03 | 0.05 |
Other Long-Term Assets | - | - | - | 0 | 0 | 0 |
Total Assets | 0 | 0.01 | 0.03 | 0.06 | 0.69 | 0.76 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.06 | 0.06 | 0.15 | 0.15 | 0.08 | 0.03 |
Short-Term Debt | 0.39 | 0.33 | 0.13 | 0.09 | 0.08 | 0.02 |
Current Portion of Leases | - | - | 0.03 | 0.03 | 0.03 | 0.02 |
Current Unearned Revenue | - | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Total Current Liabilities | 0.45 | 0.4 | 0.33 | 0.29 | 0.2 | 0.09 |
Long-Term Leases | - | - | - | 0.03 | - | 0.03 |
Total Liabilities | 0.45 | 0.4 | 0.33 | 0.32 | 0.2 | 0.12 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Additional Paid-In Capital | 32.32 | 32.31 | 32.3 | 32.3 | 32.3 | 32.29 |
Retained Earnings | -32.82 | -32.76 | -32.66 | -32.62 | -23.81 | -7.94 |
Comprehensive Income & Other | - | - | - | - | -8.06 | -23.77 |
Shareholders' Equity | -0.44 | -0.39 | -0.29 | -0.26 | 0.49 | 0.64 |
Total Liabilities & Equity | 0 | 0.01 | 0.03 | 0.06 | 0.69 | 0.76 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.39 | 0.33 | 0.15 | 0.14 | 0.1 | 0.07 |
Net Cash (Debt) | -0.38 | -0.32 | -0.15 | -0.14 | -0.1 | 0.02 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | 0.00 |
Filing Date Shares Outstanding | 60.04 | 60.04 | 60.04 | 60.04 | 60.04 | 60.04 |
Total Common Shares Outstanding | 60.04 | 60.04 | 60.04 | 60.04 | 60.04 | 60.04 |
Working Capital | -0.44 | -0.39 | -0.32 | -0.29 | 0.46 | 0.61 |
Book Value Per Share | -0.01 | -0.01 | -0.00 | -0.00 | 0.01 | 0.01 |
Tangible Book Value | -0.44 | -0.39 | -0.29 | -0.26 | 0.49 | 0.64 |
Tangible Book Value Per Share | -0.01 | -0.01 | -0.00 | -0.00 | 0.01 | 0.01 |